Impact of an automatic hospital probiotic protocol on Clostridioides ( Clostridium ) difficile infection (CDI) rates and CDI antibiotic usage in a community hospital setting
Restricted accessBrief reportFirst published online March, 2020
Impact of an automatic hospital probiotic protocol on Clostridioides ( Clostridium ) difficile infection (CDI) rates and CDI antibiotic usage in a community hospital setting
The aim of the present study was to see how widespread preventative use of the probiotic Saccharomyces boulardii via automatic protocol in hospitalised patients receiving antibacterials affected rates of hospital-associated Clostridioides (Clostridium) difficile infection (HA-CDI). Rates of HA-CDI appeared to be similar between the pre-protocol and protocol periods. Use of CDI treatment antibiotics (oral metronidazole and oral vancomycin) was also similar. Laboratory-confirmed isolation of S. boulardii from sterile body sites was identified in five patients during the protocol versus only one case in the pre-protocol years.
AllenSJWarehamKWangDBradleyCSewellBHutchingsHHarrisWDharABrownHFodenAGravenorMBMackDPhillipsCJ. (2013) High-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE). Health Technology Assessment17(57): 1–140.
2.
BarrettMLOwensPL. (2018) Clostridium Difficile Hospitalizations, 2011–2015. Rockville, MD: U.S. Agency for Healthcare Research and Quality (AHRQ). Available at: www.hcup-us.ahrq.gov/reports (accessed 10 February 2019).
3.
BoxMJOrtwineKNGoicoecheaM. (2018) No impact of probiotics to reduce Clostridium difficile infection in hospitalized patients: A real-world experience. Open Forum Infectious Diseases5(12): 192.
4.
EvansCTJohnsonS. (2015) Prevention of Clostridium difficile infection with probiotics. Clinical Infectious Diseases60(Suppl. 2): S122–128.
5.
EvansCTSafdarN. (2015) Current trends in the epidemiology and outcomes of Clostridium difficile infection. Clinical Infectious Diseases60(Suppl. 2): S66–71.
6.
JohnstonBCMaSSGoldenbergJZThorlundKVandvikPOLoebMGuyattGH. (2012) Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Annals of Internal Medicine157(12): 878–888.
7.
JohnstonBCLytvynLLoCKAllenSJWangDSzajewskaHMillerMEhrhardtSSampalisJDumanDGPozzoniPColliALönnermarkESelingerCPWongSPlummerSHicksonMPanchevaRHirschSKlarinBGoldenbergJZWangLMbuagbauwLFosterGMawASadeghiradBThabaneLMertzD. (2018) Microbial preparations (probiotics) for the prevention of Clostridium difficile infection in adults and children: An individual patient data meta-analysis of 6,851 participants. Infection Control and Hospital Epidemiology39(7): 771–781.
8.
JonesAMKuijperEJWilcoxMH. (2013) Clostridium Difficile: A European perspective. J Infect66: 115–128.
9.
McFarlandLV. (2006) Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. American Journal of Gastroenterology101(4): 812–822.
10.
ShenNTMawATmanovaLLPinoAAncyKCrawfordCVSimonMSEvansAT. (2017) Timely use of probiotics in hospitalized adults prevents Clostridium difficile Infection: A systematic review with meta-regression analysis. Gastroenterology152(8): 1889–1900.
11.
YiSHJerniganJAMcDonaldLC. (2016) Prevalence of probiotic use among inpatients: A descriptive study of 145 U.S. hospitals. American Journal of Infection Control44(5): 548–553.
